张玉顺,蒋世良,何璐

• 1:西安交通大学第一附属医院结构性心脏病科
• 2:国家心血管病中心北京协和医学院中国医学科学院阜外医院结构性心脏病中心

摘要(Abstract)：

<正>早在1877年,德国病理学家Cohnheim[1]就提出反常栓塞的概念,随之不断被尸检证实。1985年Nellessen等[2]首次用超声证实了卵圆孔未闭(patent foramen ovale,PFO)处骑跨血栓。1994年Brogno等[3]不仅在

关键词(KeyWords)： 卵圆孔未闭;隐源性卒中

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 张玉顺,蒋世良,何璐

参考文献(References)：

• [1]Cohnheim J.Thrombose und Embolie.In:VorlesungenüberAllge meinepathologie.Berlin:Hirschwald,Vol 1,1877:134.
• [2]Nellessen U,Daniel WG,Matheis G,et al.Impending paradoxical embolism from atrial thrombus:correct diagnosis by transesophageal echocardiography and prevention by surgery.J Am Coll Cardiol,1985,5(4):1002-1004.
• [3]Brogno DJ,Lancaster G,Rosenbaum M.Embolus Interuptus.NEngl J Med,1994,330(24):1761-1762.
• [4]Bridges ND,Hellenbrand W,Latson L,et al.Transcatheter closure of patent foramen ovale after presumed paradoxical embolism.Circulation,1992,86(6):1902-1908.
• [5]Wahl A,Jüni P,Mono ML,et al.Long-term propensity scorematched comparison of percutaneous closure of patent foramen oval with medical treatment after paradoxical embolism.Circulation,2012,125(6):803-812.
• [6]Agarwal S,Bajaj NS,Kumbhani DJ,et al.Meta-analysis of transcatheter closure versus medical therapy for patent foramen ovale in prevention of recurrent neurological events after presumed paradoxical embolism.JACC Cardiovasc Interv,2012,5(7):777-789.
• [7]Gafoor S,Franke J,Boehm P,et al.Leaving no hole unclosed:left atrial appendage occlusion in patients having closure of patent foramen ovale or atrial septal defect.J Interv Cardiol,2014,27(4):414-422.
• [8]Furlan AJ,Reisman M,Massaro J,et al.Closure or medical therapy for cryptogenic stroke with patent foramen ovale.N Engl JMed,2012,366(11):991-999.
• [9]Carroll JD,Saver JL,Thaler DE,et al.Closure of patent foramen ovale versus medical therapy after cryptogenic stroke.N Engl JMed,2013,368(12):1092-1100.
• [10]Meier B,Kalesan B,Mattle HP,etal.Percutaneous closure of patent foramen ovale in cryptogenic embolism.N Engl J Med,2013,368(12):1083-1091.
• [11]Taaffe M,Fischer E,Baranowski A,et al.Comparison of three patent foramen ovale closure devices in a randomized trial(Amplatzer versus Cardioseal-StarFlex versus Helexoccluder).Am JCardiol,2008,101(9):1353-1358.
• [12]Hornung M,Bertog SC,Franke J,et al.Long-term results of a randomized trial comparing three diff erent devices for percutaneous closure of a Patent foramen ovale.Eur Heart J,2013,34(43):3362-3369.
• [13]Mas JL,Derumeaux G,Guillon B,et al.Patent foramen ovale closure or anticoagulation vs.antiplatelets after stroke.N Engl JMed,2017,377(11):1011-1021.
• [14]S?ndergaard L,Kasner SE,Rhodes JF,et al.Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke.N Engl J Med,2017,377:1033-1042.
• [15]Saver JL,Carroll JD,Thaler DE,et al.Long-term outcomes of patent foramen ovale closure or medical therapy after stroke.N Engl J Med,2017,377(11):1022-1032.
• [16]Diener HC,Grau AJ,Baldus S,et al.Cryptogenic stroke and patent foramen ovale:S2e guidelines.Nervenarzt,2018,89(10):1143-1153.
• [17]R?ther J,K?hrmann M,Steiner T,et al.Closure of patent foramen ovale for cryptogenic stroke-"should be considered"!Nervenarzt,2018,89(10):1154-1155.
• [18]Lee PH,Song JK,Kim JS,et al.Cryptogenic stroke and high-risk patent foramen ovale:the DEFENSE-PFO trial.J Am Coll Cardiol,2018,71(20):2335-2342.
• [19]Kuijpers T,Spencer FA,Siemieniuk RAC,et al.Patent foramen ovale closure,antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke?A clinical practice guideline.BMJ,2018,362:k2515.